Study guide
11.2 Adherence, Discontinuation and Participant Choice
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
11.2 Adherence, Discontinuation and Participant Choice
Key Takeaways Explain This Topic AI
Product discontinuation and withdrawal of all follow-up are distinct statuses.
Return counts estimate unreturned product rather than proven ingestion.
Participants need not provide a reason for withdrawing.
Last updated: October 2026
Adherence, Discontinuation and Participant Choice
Review the actual prescribed regimen, dispensing, returns, medical holds, participant report and relevant clinical events. A low tablet count can reflect missed doses, lost supplies, an incorrect denominator or recording error. A participant may misunderstand instructions or stop because of an unreported adverse effect. Ask respectfully and involve the investigator, avoiding an accusation based solely on a percentage.
For a fixed-dose example, a participant receives 28 tablets for one tablet daily over 28 days. Four tablets remain and there were no authorised holds. The simple return-based estimate is (28 − 4)/28 × 100 = 85.7% , to one decimal place. It estimates unreturned tablets, not observed ingestion. If two tablets were lost, the count cannot establish that 24 were swallowed. Record the uncertainty and apply the protocol's evaluation process.
Do not assume a universal acceptable adherence range. The clinical importance depends on the product, schedule and study question. Missing one dose of a narrow-margin treatment may matter differently from a missed optional questionnaire. A protocol threshold defines an operational action; it does not replace medical assessment or prove dishonesty.
Participant responsibilities should be understandable
The consent process and study instructions should explain relevant visits, product use, diaries, reporting of symptoms, prohibited treatments and contact routes. Provide information suited to the participant's language, abilities and technology access. Check understanding and practical barriers. A participant cannot reliably follow a diary schedule if they were never shown how to use the application or what to do during a connection failure.
Finding Clarification needed Appropriate response
Several missed doses Was there a medical hold, misunderstanding or adverse effect? Investigator review and protocol-based counselling/documentation
Repeated missed visits Is the burden or contact process unworkable? Discuss permitted options without pressure
Missing diary entries Was the device unavailable, unused or not transmitting? Preserve timing and resolve under the data plan
Request to stop medication Does the participant want any continued follow-up? Respect the decision and explain available options
Documenting discontinuation
Capture the relevant date, activity stopped, reason if provided, investigator assessment, product disposition, safety status and permitted follow-up. Distinguish treatment discontinuation from withdrawal of further contact. A participant is not obliged to explain withdrawal. Staff may make a reasonable respectful effort to understand concerns and offer permissible alternatives, but should not coerce a reconsideration.
Suppose someone stops dosing because of nausea but agrees to telephone safety follow-up and the planned final assessment. The record should preserve those distinctions. The site should not classify the person as lost to follow-up, erase earlier adverse events or automatically cancel every future activity. If the person later declines all contact, update the scope accurately and follow the applicable process.
For a protocol-mandated safety stop, verify that qualified staff reviewed the triggering information and implemented the appropriate care and notifications. A stopping decision may require prompt sponsor communication and ethics/authority reporting depending on the circumstances. Do not assume that following a prewritten stopping rule is itself a protocol deviation. Failing to follow that rule can be a significant concern.
Data and safety after stopping
The handling of already collected information should be described in the protocol/consent process and follow applicable requirements. Withdrawal does not automatically require deletion of all existing research data, and a desire for complete data does not authorise new collection without permission. Preserve the decision record and seek responsible guidance when scope is uncertain.
Safety follow-up should respect the protocol, applicable requirements and participant choice. Track outstanding clinical information, reasonable contact efforts and the point at which further attempts are no longer permitted or appropriate. Do not mark an event resolved merely because the participant is unreachable. Retain an honest status such as ongoing or unknown when supported by the facts.
At close-out, reconcile participant status across the source, EDC, product records and tracking systems. Explain legitimate differences, such as a product stop date preceding the final follow-up visit. These distinctions support both participant protection and interpretation of the treatment effect, especially when intercurrent events and missing data affect the planned analysis.
Identify the interest before deciding how to manage it
A conflict of interest arises when a secondary interest could influence, or appear to influence, professional judgement about participant welfare or research integrity. Financial interests are one example, but professional advancement, family relationships, employment hierarchies and institutional recruitment pressure can also matter. A conflict is not proof that misconduct occurred; an undisclosed or unmanaged conflict can undermine independent decisions.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E2A , WMA Declaration of Helsinki, 2024 .